© Reuters. FILE PHOTO: Ducklings are seen inside a poultry farm in Castelnau-Tursan, France, January 24, 2023. REUTERS/Stephane Mahe/File Photo/File Photo
Add to/Remove from Watchlist
Add to Watchlist
Position added successfully to:
Please name your holdings portfolio
Create New Watchlist
Create a new holdings portfolio
+ Add another position
PARIS (Reuters) – France confirmed its aim to launch a vaccination programme against bird flu in the autumn after results from a series of tests on the vaccination of ducks showed “satisfactory effectiveness”, the farm ministry said.
A severe strain of highly pathogenic avian influenza, commonly called bird flu, has ravaged poultry production around the world, leading to the culling of over 200 million birds in the past 18 months.
France has been the worst hit country in the European Union and is facing a strong resurgence of outbreaks since early this month in the southwestern part of the country, mainly among ducks.
It had already launched a pre-order of 80 million vaccines last month, which needed to be confirmed based on final tests carried out by French health safety agency ANSES.
“These favourable results provided sufficient guarantees to launch a vaccination campaign as early as autumn 2023,” the farm ministry wrote on its website.
Governments, often shy to use vaccination due to the trade restrictions it can entail, have increasingly considered adopting them to stem the spread of the virus and avoid interhuman transmission.
The results of the tests demonstrated a good control of virus transmission in vaccinated mule ducks, a differentiation between infected and vaccinated animals, known as the DIVA principle, and a reduction in virus excretion by vaccinated birds, the test conclusions said.
France has mandated two companies, France’s Ceva (NASDAQ:CEVA) Animal Health and Germany’s Boehringher Ingelheim, to develop bird flu vaccines for ducks.
Several other EU countries have been carrying out tests, including the Netherlands on laying hens and Italy on turkeys.
First results in the Netherlands showed the vaccines tested were efficient.